India’s largest multispecialty hospital network by bed capacity opened more than 10% above its offer price. In another deal, KKR has acquired Hyderabad-based hospital chain Medicover Hospitals India, as the country’s private healthcare market grows.
Temasek's SeaTown Holdings-backed Foundation Healthcare Holdings debuts on the SGX Mainboard, while Chinese electronic components manufacturer Luxshare leads lukewarm IPOs in Hong Kong.
A core product for Type 2 diabetes is expected to commercially launch in mainland China by the end of this year, subject to regulatory approval; CICC led the transaction.
Demographics, economic growth and government initiatives are bolstering demand to provide more investment into India's healthcare infrastructure, as overall PE sentiment in the region improves.
The $400m deal will see global PE firm acquire up to 54% of equity from CVC, and up to a total 77% stake of the Indian cancer care specialist; KKR made several significant investments into Indian healthcare firms last year, as regional PE deals bounceback.
The $680m deal includes UCB's brands Keppra, Vimpat, Neupro, Zyrtec, Xyzal, and its Zhuhai manufacturing site, and was made in partnership with Mubadala Investment Co.
Insighta, valued at $200m, uses a system designed to detect DNA methylation aberrations in cell-free DNA in bodily fluids such as blood; Prenetics has reduced its stake in the firm.
